Characterization of domain-selective inhibitor binding in angiotensin-converting enzyme using a novel derivative of lisinopril
Journal Article
2010
Permanent link to this Item
Authors
Journal Title
Biochemical Journal
Link to Journal
Journal ISSN
Volume Title
Publisher
Portland Press
Publisher
University of Cape Town
License
Series
Abstract
Human ACE (angiotensin-converting enzyme) (EC 3.4.15.1) is an important drug target because of its role in the regulation of blood pressure via the renin–angiotensin–aldosterone system. Somatic ACE comprises two homologous domains, the differing substrate preferences of which present a new avenue for domainselective inhibitor design. We have co-crystallized lisW-S, a Cdomain-selective derivative of the drug lisinopril, with human testis ACE and determined a structure using X-ray crystallography to a resolution of 2.30 Å (1 Å = 0.1 nm). In this structure, lisW-S is seen to have a similar binding mode to its parent compound lisinopril, but the P2 tryptophan moiety takes a different conformation to that seen in other inhibitors having a tryptophan residue in this position. We have examined further the domain-specific interactions of this inhibitor by mutating Cdomain-specific active-site residues to their N domain equivalents, then assessing the effect of the mutation on inhibition by lisWS using a fluorescence-based assay. Kinetics analysis shows a 258-fold domain-selectivity that is largely due to the co-operative effect of C-domain-specific residues in the S2 subsite. The high affinity and selectivity of this inhibitor make it a good lead candidate for cardiovascular drug development.
Description
Keywords
Reference:
Watermeyer, J. M., Kröger, W. L., O'Neill, H. G., Sewell, B. T., & Sturrock, E. D. (2010). Characterization of domain-selective inhibitor binding in angiotensin-converting enzyme using a novel derivative of lisinopril. Biochemical Journal, 428(1), 67-74.